N/A N=11,980 mFOCUS (Multilevel FOllow-up of Cancer Screening)
Cancer
Primary: Completion of Follow-up Test — 672; 796; 831; 1062 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
Biological Availability
Primary: AUCinf of Nirmatrelvir Following the Administration of Nirmatrelvir/Ritonavir in Different Delivery Vehicles — 27090; 30650; 33030; 34000 nanogram*hour per milliliter…
N/A N=192 A Study Aimed to Assess the Needs of Subjects With Sickle Cell Disease and Healthcare Professionals Managing Sickle Cell Disease Patients in Selected Nigerian Centres
Sickle Cell Disease
Primary: Level of Satisfaction on SCD Current Treatment and Management — 4.12 score on a scale
Phase 1 N=39 STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Diabetes Mellitus, Type 2 · Renal Impairment · Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961 — 38.80; 38.67; 39.19; 56.68 nanograms/milliliter (ng/mL)
Phase 2 N=80 An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
Respiratory Viral Infection · Antiviral Treatment · COVID-19
Primary: Number of Participants With Viral Illness — 12; 30 Participants
N/A N=12 Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women
Central Obesity
Primary: Body Fat (kg) — 40.96; 40.12; 2.94; 4.26 kg
Phase 1 N=37 A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate
Healthy
Primary: The Incidence, Severity and Relationship of Treatment-Emergent Adverse Events (TEAEs). — 10; 7; 4; 5 participants
N/A N=241 Cognition and Smoking Relapse (HCS)
Smoking Cessation
Primary: Cognitive Function — 0.125; -.093; -.059; -.008 z-score
Phase 1 N=24 Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Malaria
Primary: Characterize the PK/PD Relationship Between OZ439 and PQP Plasma Concentrations (Cmax) — 0.2582; 0.4145; 0.8829; 0.6835 ng/L
Phase 3 N=240 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure at Week 4 — -6.2; -6.8 mmHg — p=0.0231
Phase 2 N=78 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Small Cell Lung Carcinoma · Non Small Cell Lung Carcinoma · Irinotecan Sensitive Cancers
Primary: Phase Ib: Maximum Tolerated Dose — 20; 36 mg/m^2 Carfilzomib
N/A N=42 Acute Feasibility Investigation of a New S-ICD Electrode
Ventricular Fibrillation
Primary: Defibrillation Threshold (DFT) of the New Shock Electrode Configuration in Joules — 27.0; 31.5 Joules
Phase 3 N=176 Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Nervous System Disease · Genetic Syndrome
Primary: Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS) — 0.8; 1.0; 2.3 score on a scale — p=0.0847
Phase 2 N=71 A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
Atopic Dermatitis
Primary: Number of Participants With Investigator Global Assessment (IGA) Response — 5; 2; 0; 0 Participants
Phase 3 N=477 LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of…